AACR Grantee Identifies Novel Combination Therapy for Epithelial Ovarian Cancer
Epithelial ovarian cancer is by far the most common ovarian cancer subtype, accounting for 90 percent of ovarian cancers. The...
Tag: Ovarian cancer
Home »
Epithelial ovarian cancer is by far the most common ovarian cancer subtype, accounting for 90 percent of ovarian cancers. The...
The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held this year at the Hynes Convention Center in...
On Wednesday, the U.S. Food and Drug Administration (FDA) expanded the use of the molecularly targeted therapeutic niraparib (Zejula)...
September is Ovarian Cancer Awareness Month. It’s an apt time for the American Association for Cancer Research (AACR) Advances...
Dong-Joo (Ellen) Cheon, PhD, Assistant Professor of Regenerative and Cancer Cell Biology at Albany Medical College and the 2017...
For the second consecutive year, the American Association for Cancer Research (AACR) has been designated the beneficiary of Party...
On Sunday, almost 300 of the greatest minds in ovarian cancer research will come together in Pittsburgh to discuss...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic niraparib (Zejula) for the...
On Monday, the U.S. Food and Drug Administration (FDA) announced good news for a subgroup of patients with ovarian...
New imaging system can help surgeons get more cancer out; Presurgery chemo can make ovarian cancer responsive to immunotherapy...